ZyVersa TherapeuticsZVSA 25 Net Debt Paydown Yield % is 0% as of Jul. 12, 2026. GuruFocus rates ZVSA with a GF Score™ of 25/100. The stock has 1 warning sign investors should review. Among 1,160 Biotechnology companies, ZyVersa Therapeutics ranks worse than 86206.81% on this metric.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, ZyVersa Therapeutics's Net Debt Paydown Yield % was 0%.
ZyVersa Therapeutics (OTCPK:ZVSA) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
ZyVersa Therapeutics Net Debt Paydown Yield % Related Terms
ZyVersa Therapeutics Net Debt Paydown Yield % Historical Data
* Premium members only.
The historical data trend for ZyVersa Therapeutics's Net Debt Paydown Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZyVersa Therapeutics Net Debt Paydown Yield % Chart
ZVSA vs AXIM, ISCO, HEPA: Net Debt Paydown Yield % Comparison
For the Biotechnology subindustry, ZyVersa Therapeutics's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ZyVersa Therapeutics Net Debt Paydown Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ZyVersa Therapeutics's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where ZyVersa Therapeutics's Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
ZyVersa Therapeutics (ZVSA) has a Net Debt Paydown Yield % of 0% as of Jul. 12, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on ZyVersa Therapeutics and its competitors. Over the past decade, ZyVersa Therapeutics' Net Debt Paydown Yield % has ranged from 2.44 to 138.91. According to the industry distribution chart, ZyVersa Therapeutics ranks #999999 out of 1160 companies in the Biotechnology industry.
Is ZyVersa Therapeutics' Net Debt Paydown Yield % too high?
ZyVersa Therapeutics' current Net Debt Paydown Yield % is 0%. Over the past 10 years, this metric has ranged from a low of 2.44 to a high of 138.91. Based on the distribution chart, ZyVersa Therapeutics ranks #999999 out of 1160 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ZyVersa Therapeutics has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does ZyVersa Therapeutics' Net Debt Paydown Yield % compare to AXIM and ISCO?
According to the Biotechnology industry distribution chart, ZyVersa Therapeutics ranks #999999 out of 1160 companies for Net Debt Paydown Yield %. This places ZyVersa Therapeutics in the lower half of its industry. The industry median Net Debt Paydown Yield % is 0.04. Historically, ZyVersa Therapeutics' own Net Debt Paydown Yield % has ranged from 2.44 to 138.91 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Biotechnology company?
The median Net Debt Paydown Yield % among Biotechnology companies is 0.04, based on 1,160 companies in the industry. Companies in the top quartile (top 25%) have a Net Debt Paydown Yield % significantly above this median, while those in the bottom quartile fall well below. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on ZyVersa Therapeutics and its competitors. For the Biotechnology industry, the median Net Debt Paydown Yield % is 0.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ZyVersa Therapeutics's current Net Debt Paydown Yield % is 0%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ZyVersa Therapeutics stock overvalued right now?
ZyVersa Therapeutics (ZVSA) has a current Net Debt Paydown Yield % of 0%. The current Net Debt Paydown Yield % is 0%. ZyVersa Therapeutics' overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For ZyVersa Therapeutics (ZVSA), the current Net Debt Paydown Yield % is 0% as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
25GF Score
Get the complete analysis for ZVSA
Net Debt Paydown Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZVSA has been successfully added to your 
